MoxifloxacinFluoroquinolone antibiotic,board specturm CAS# 151096-09-2 |
- Orbifloxacin
Catalog No.:BCC4689
CAS No.:113617-63-3
- Cisplatin
Catalog No.:BCN1552
CAS No.:14283-03-5
- Ciclopirox ethanolamine
Catalog No.:BCC4372
CAS No.:41621-49-2
- Carbenicillin
Catalog No.:BCC5192
CAS No.:4697-36-3
- Sulconazole Nitrate
Catalog No.:BCC4853
CAS No.:61318-91-0
- Sertaconazole nitrate
Catalog No.:BCC4716
CAS No.:99592-39-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 151096-09-2 | SDF | Download SDF |
| PubChem ID | 152946 | Appearance | Powder |
| Formula | C21H24FN3O4 | M.Wt | 401.43 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid | ||
| SMILES | COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O | ||
| Standard InChIKey | FABPRXSRWADJSP-MEDUHNTESA-N | ||
| Standard InChI | InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent.
Target: Antibacterial
Moxifloxacin is an extended-spectrum fluoroquinolone which has improved coverage against gram-positive cocci and atypical pathogens compared with older fluoroquinolone agents, while retaining good activity against gram-negative bacteria. The antibacterial spectrum of moxifloxacin includes all major upper and lower respiratory tract pathogens; it is one of the most active fluoroquinolones against pneumococci, including penicillin- and macrolide-resistant strains [1]. Moxifloxacin has limited phototoxic potential. In clinical trials, moxifloxacin had clinical success rates of 88-97% and bacteriologic eradication rates of 90-97%. Moxifloxacin is a safe and effective antimicrobial that will be useful for treating acute sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia [2]. Moxifloxacin possibly stimulates lipid peroxidation and enhances phagocytosis, as depicted by MDA production and survival prolongation, without being toxic as depicted by white blood cell count [3].
Clinical indications: Abdominal abscess; Acute bronchitis; Acute sinusitis; Bacterial infection
Toxicity: Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg. References: | |||||
Moxifloxacin Dilution Calculator
Moxifloxacin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4911 mL | 12.4555 mL | 24.9109 mL | 49.8219 mL | 62.2774 mL |
| 5 mM | 0.4982 mL | 2.4911 mL | 4.9822 mL | 9.9644 mL | 12.4555 mL |
| 10 mM | 0.2491 mL | 1.2455 mL | 2.4911 mL | 4.9822 mL | 6.2277 mL |
| 50 mM | 0.0498 mL | 0.2491 mL | 0.4982 mL | 0.9964 mL | 1.2455 mL |
| 100 mM | 0.0249 mL | 0.1246 mL | 0.2491 mL | 0.4982 mL | 0.6228 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Moxifloxacin is an orally bio-available, broad spectrum bacterial gyrase-inhibiting fluoroquinolone antibiotic [1].
Moxifloxacin at 50 μg/mL has been reported to induce a significant reduction of viable cells. A remarkable anti-proliferative activity of moxifloxacin has been proved in the concentrations between 50 and 1500 μg/mL. Moreover, moxifloxacin could lead to signs of cellular damage which were seen like binucleation in a dose-dependent manner [2].
Rats intravenously injected with moxifloxacin at 100 mg/kg have shown the increase of Serum glucose and serum epinephrine concentrations as well as the release of histamine. However, moxifloxacin at 75 mg/kg did not show any effects on serum epinephrine, glucose or histamine concentrations increase [3].
References:
[1] Iatropoulos MJ1, Jeffrey AM, Enzmann HG, von Keutz E, Schlueter G, Williams GM. Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of moxifloxacin, a quinolone antibiotic. Exp Toxicol Pathol. 2001 Oct;53(5):345-57.
[2] Sobolewska B1, Hofmann J, Spitzer MS, Bartz-Schmidt KU, Szurman P, Yoeruek E. Antiproliferative and cytotoxic properties of moxifloxacin on rat retinal ganglion cells. Curr Eye Res. 2013 Jun;38(6):662-9.
[3] Ishiwata Y1, Takahashi Y, Nagata M, Yasuhara M. Effects of moxifloxacin on serum glucose concentrations in rats. Biol Pharm Bull. 2013;36(4):686-90.
- L-701,252
Catalog No.:BCC6755
CAS No.:151057-13-5
- DOXO-EMCH
Catalog No.:BCC1537
CAS No.:151038-96-9
- H-Phe-OtBu.HCl
Catalog No.:BCC3011
CAS No.:15100-75-1
- Boc-Lys(Boc)-OH.DCHA
Catalog No.:BCC3413
CAS No.:15098-69-8
- 7,8-Didehydrocimigenol
Catalog No.:BCN3343
CAS No.:150972-72-8
- 2,4,4'-Trihydroxydihydrochalcone
Catalog No.:BCN7365
CAS No.:15097-74-2
- Tirofiban hydrochloride monohydrate
Catalog No.:BCC2003
CAS No.:150915-40-5
- D-allo-Ile-OH
Catalog No.:BCC2966
CAS No.:1509-35-9
- Aurantiamide benzoate
Catalog No.:BCN8043
CAS No.:150881-02-0
- Euonymine
Catalog No.:BCN3084
CAS No.:150881-01-9
- Bis(phenylacetyl) disulfide
Catalog No.:BCC8887
CAS No.:15088-78-5
- Uralenol-3-methylether
Catalog No.:BCN7993
CAS No.:150853-98-8
- Haloperidol hydrochloride
Catalog No.:BCC4251
CAS No.:1511-16-6
- 4-Difluoromethoxy-3-hydroxybenzaldehyde
Catalog No.:BCC8706
CAS No.:151103-08-1
- 8-(6-Hydroperoxy-3,7-dimethyl-2,7-octadienyloxy)psoralen
Catalog No.:BCN1558
CAS No.:151121-39-0
- CL 316243 disodium salt
Catalog No.:BCC7091
CAS No.:151126-84-0
- 4'-Hydroxy-2,4-dimethoxychalcone
Catalog No.:BCC8708
CAS No.:151135-64-7
- Borapetoside D
Catalog No.:BCN6612
CAS No.:151200-48-5
- Borapetoside E
Catalog No.:BCN6571
CAS No.:151200-49-6
- Borapetoside F
Catalog No.:BCN6413
CAS No.:151200-50-9
- Poricoic acid AM
Catalog No.:BCN8499
CAS No.:151200-92-9
- Primin
Catalog No.:BCN2729
CAS No.:15121-94-5
- CP 135807
Catalog No.:BCC7774
CAS No.:151272-90-1
- Genkwanol C
Catalog No.:BCN8012
CAS No.:151283-11-3
Efficacy of Triple Antibiotic Paste, Moxifloxacin, Calcium Hydroxide And 2% Chlorhexidine Gel In Elimination of E. Faecalis: An In vitro Study.[Pubmed:28274034]
J Clin Diagn Res. 2017 Jan;11(1):ZC06-ZC09.
INTRODUCTION: Root canal treatment is incomplete without usage of intra canal medicaments. They help in the reduction of bacterial count and its by-products, making canals clean and decreasing postoperative pains. AIM: The aim of this study was to evaluate and compare the antimicrobial activity of triple antibiotic paste, Moxifloxacin, calcium hydroxide and 2% Chlorhexidine (CHX) gel in elimination of Enterococcous faecalis (E. faecalis). MATERIALS AND METHODS: Seventy-five root blocks were obtained from extracted single rooted human teeth. The canal diameter was increased using Gates- Glidden drill up to size 3 and then contaminated with E. faecalis for 21 days. The contaminated samples were then divided into following 5 groups. Group 1: Saline (negative group), Group 2: Calcium hydroxide Ca(OH)2, Group 3: 2% CHX gel, Group 4: Triple Antibiotic Paste (TAP) (50 mug - metronidazole of 400 mg, 50 mug - minocycline of 100 mg, 50 mug - ciprofloxacin of 100 mg) and Group 5: Moxifloxacin (50 mug - Moxifloxacin of 400 mg). Dentin debris was obtained at the end of first, 7(th), and 10(th) day using Gates Glidden drill sizes 4 and 5. The bacterial load was assessed by counting the number of Colony Forming Units (CFUs). The data were analyzed with the ANOVA and Post-Hoc tests to assess the differences in antibacterial efficacy between groups (p=<0.001). RESULTS: A 2% CHX gel alone completely inhibited the growth of E. faecalis after one, seven and 10 days. The 2% CHX gel was the most effective medicament against E. faecalis, as it showed significant differences with normal saline, calcium hydroxide, Moxifloxacin or triple antibiotic paste at all time intervals. The triple antibiotic paste group showed a moderate antibacterial effect as its difference with all group was significantly better at all days. Moxifloxacin was more effective than calcium hydroxide on 7(th) and 10(th) day. CONCLUSION: Best antimicrobial efficacy was shown by 2% CHX gel. Moxifloxacin was equally efficient compared to triple antibiotic paste against E. faecalis at longer intervals of time.
